Second stem cell transplant shows promise for returning myeloma

NCT ID NCT01009840

Completed Disease control Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a combination of two drugs, busulfan and bortezomib, given before a second stem cell transplant in 30 patients with multiple myeloma that had returned after a previous transplant. The goal was to see if this approach could control the disease. Results showed that many patients had a reduction in cancer levels six months after the transplant.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: busulfan and bortezomib
What this could lead to: If successful, this approach could offer a treatment option for patients with multiple myeloma that has returned after a first stem cell transplant.
What could go wrong: This is a small, early-phase study with only 30 participants. The results may not apply to all patients, and the treatment carries risks like infection and organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Arizona Cancer Center

Tucson, Arizona, 85724, United States
Blood and Marrow Transplant Group of Georgia

Atlanta, Georgia, 30342, United States
Huntsman Cancer Institute

Salt Lake City, Utah, 84112, United States
Indiana University Melvin and Bren Simon Cancer Center

Indianapolis, Indiana, 46202, United States
Karmanos Cancer Institute

Detroit, Michigan, 48201, United States
Loyola University Medical Center

Maywood, Illinois, 60153, United States
Princess Margaret Hospital

Toronto, Ontario, M5G 2M9, Canada
Queen Elizabeth II Health Sciences Centre

Halifax, Nova Scotia, B3H 2Y9, Canada
South Texas Veterans Health Care System

San Antonio, Texas, 78229, United States
Texas Transplant Physician Group, PLLC

San Antonio, Texas, 78229, United States
The Western Pennsylvania Hospital

Pittsburgh, Pennsylvania, 15224, United States
University of Maryland School of Medicine - Marlene & Stewart Greenebaum Cancer Center

Baltimore, Maryland, 21201, United States
University of Pennsylvania -Abramson Cancer Center

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.